Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • baohua100
    Senior Member
    • Jun 2008
    • 103

    RPKM for alternative splicing genes?

    When calculate a PRKM for a gene locus

    R=109C/NL
    where C is the number of mappable reads that fell onto the gene’s exons, N is the total number of mappable reads in the experiment, and L is the sum of the exons in base pairs.

    for genes with alternative splicing, like a intron retain, how to determin the L ? is this intron count into the L ?
  • juan
    Member
    • Aug 2009
    • 14

    #2
    L is the sum of bases for the gene, not the exon, right?

    RPKM does not account for splicing, nor does it distinguish between transcript isoforms.

    I would include the intron in the L.

    Comment

    • steven
      Senior Member
      • Aug 2009
      • 269

      #3
      I would suggest to "project" or "collapse" all the exons onto the genomic sequence and work in genomic space. Then your C will be the number of mappable reads that fall in an exonic region (of one of the transcripts of your gene), and L the total exonic space of the gene (number of genomic positions that are found in a mature transcript, not the "sum of the exons"). Like this, overlapping parts of exons from different transcripts are not counted several times. Also, transcribed areas that are alternatively retained into splice products (like your "retained intron") will be part of L.

      AFAIK, nothing has been published yet regarding relative quantification of transcript variants from alternative splicing. Does anyone have more info?

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        Today, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        Yesterday, 05:17 AM
      • GATTACAT
        Reply to Nine Things a Sample Prep Scientist Thinks About Before Sequencing
        by GATTACAT
        Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.
        07-01-2026, 11:43 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Today, 10:04 AM
      0 responses
      7 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, Yesterday, 10:08 AM
      0 responses
      6 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-07-2026, 11:05 AM
      0 responses
      9 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-02-2026, 11:08 AM
      0 responses
      31 views
      0 reactions
      Last Post SEQadmin2  
      Working...